Recruiting

1/2

40

RoW

TQ-A3334, Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Non-small Cell Lung Cancer

01/21

01/21

Recruiting

1

81

 

The first group (pretest) of 2 subjects, 2 patients were all tested drugs, both men and women, once administered, fasting conditions, 24h (D2), 72h (D4), 120h after administration ( Durability assessment at D6), 144h (D7), D14±2, D21±2, and D28±2 visits, and if D1-D7 tolerability evaluation is tolerated, it ;In the second group of 10 subjects, 8 received the test drug and 2 received the placebo, with a similar proportion of men and women. Each group was dosed once and administered under fasting conditions, at the time of 24h (D2), 72h (D4), 120h (D6), 144h (D7), D14±2, D21±2, and D28±2 visits. T ;In the third group of 10 subjects, 8 received the test drug and 2 received the placebo, with a similar proportion of men and women. Each group was dosed once and administered under fasting conditions, at the time of 24h (D2), 72h (D4), 120h (D6), 144h (D7), D14±2, D21±2, and D28±2 visits. To ;The fourth group consisted of 10 subjects, of whom 8 received the test drug and 2 received the placebo, with a similar proportion of men and women. Each group was dosed once and administered under fasting conditions, at the time of 24h (D2), 72h (D4), 120h (D6), 144h (D7), D14±2, D21±2, and ;The fifth group (4.0mg dose group) needs to complete a single dose, food pharmacokinetic study, a total of 18 subjects, group A 10 subjects, group B 8 subjects. A group of subjects need to participate in a single dose, food pharmacokinetic effects of the study, B group only participated in the s ;The sixth group consisted of 10 subjects, of whom 8 received the test drug and 2 received the placebo. The proportion of men and women was similar. Each group was dosed once and administered under fasting conditions, at the time of 24h (D2), 72h (D4), 120h (D6), 144h (D7), D14±2, D21±2, and ;The seventh group consisted of 10 subjects, of whom 8 received the test drug and 2 received the placebo, with a similar proportion of men and women. Each group was dosed once and administered under fasting conditions, at the time of 24h (D2), 72h (D4), 120h (D6), 144h (D7), D14±2, D21±2, and ;After the end of the sixth group of trials, the investigator and the sponsor decide whether or not to perform the eighth group of multiple dose clinical studies and multiple dose studies. The eighth group required the completion of multiple dose clinical studies with a total of 11 subjects, of whom&

The First Hospital of Jilin University; Chia Tai Tianqing Pharmaceutical Group Co, Ltd, Chia Tai Tianqing Pharmaceutical Group Co,Ltd

HBV

 

 

Not yet recruiting

1

90

 

Ten subjects were enrolled,8 received the trial drug and 2 received placebo, and the male-to-female ratio was close to 1:1. 0.5 mg was administered at D1, D3, D5, D7, D9, and safety was checked on D5, D10 and D14, and tolerability was evaluated on D5, D14.; Ten subjects were enrolled,8 received the trial drug and 2 received placebo, and the male-to-female ratio was close to 1:1. 1.0 mg was administered at D1, D3, D5, D7, D9, and safety was checked on D5, D10 and D14, and tolerability was evaluated on D5, D14.; Ten subjects were enrolled,8 received the trial drug and 2 received placebo, and the male-to-female ratio was close to 1:1. 0.5 mg each time for 10 consecutive days, and safety tests were performed on D5, D10 and D14, and tolerability was evaluated on D5 and D14.; Ten subjects were enrolled,8 received the trial drug and 2 received placebo, and the male-to-female ratio was close to 1:1. 2.0 mg was administered on D1, D4, D7, D10; The safety of D5, D10 and D14 was checked, and the tolerability evaluation was performed on D5, D14.; Ten subjects were enrolled,8 received the trial drug and 2 received placebo, and the male-to-female ratio was close to 1:1. 2.0 mg was administered on D1, D3, D5, D7, D9, and safety was checked on D5, D10 and D14, and tolerability was evaluated on D5, D14.; Ten subjects were enrolled,8 received the trial drug and 2 received placebo, and the male-to-female ratio was close to 1:1. 0.2 mg each time for 10 consecutive days, and safety tests were performed on D5, D10 and D14, and tolerability was evaluated on D5 and D14.; Ten subjects were enrolled,8 received the trial drug and 2 received placebo, and the male-to-female ratio was close to 1:1. 1.5 mg was administered on D1, D4, D7, D10; The safety of D5, D10 and D14 was checked, and the tolerability evaluation was performed on D5, D14.; Ten subjects were enrolled,8 received the trial drug and 2 received placebo, and the male-to-female ratio was close to 1:1. 1.5 mg was administered on D1, D3, D5, D7, D9, and safety was checked on D5, D10 and D14, and tolerability was evaluated on D5, D14.; Ten subjects were enrolled,8 received the trial drug and 2 received placebo, and the male-to-female ratio was close to 1:1. 1.0 mg each time for 10 consecutive days, and safety tests were performed on D5, D10 and D14, and tolerability was evaluated on D5 and D14.

The First Hospital of Jilin University; Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Fully self-financed

Hepatitis B